Tin tức & Cập nhật
Xem bài viết Hô hấp
Xem

OS benefit of adjuvant osimertinib in resected EGFR-mutated NSCLC persists at 8th year
Adjuvant osimertinib continues to demonstrate an overall survival (OS) benefit over placebo in patients with resected EGFR-mutated (exon 19 del/L858R) non-small cell lung cancer (NSCLC), according to the 8-year exploratory analysis of the phase III ADAURA trial presented at WCLC 2026.

Thymic radiation may cause metastasis, death in NSCLC patients
Patients with nonsmall cell lung cancer (NSCLC) who have been exposed to thymic radiation appear to be at increased risks of metastasis and mortality, particularly those with preserved thymic function, a recent study has found.

Asthma: No difference in pneumonia risk between budesonide and fluticasone users
A territory-wide retrospective study of >16,000 adult patients with moderate-to-severe asthma finds no difference in risk of pneumonia between budesonide and fluticasone propionate (FP) or fluticasone furoate (FF) users.

Benralizumab provides cough, dyspnoea relief in severe asthma
In a post hoc analysis of the phase III MIRACLE trial, benralizumab relieves cough and/or dyspnoea and improves cough-specific health-related quality of life (HRQoL) in individuals with severe eosinophilic asthma (SEA).

Sacituzumab govitecan plus pembrolizumab no better than monotherapy in metastatic NSCLC
Combination treatment with sacituzumab govitecan (SG) and pembrolizumab has resulted in a numerically longer progression-free survival (PFS) compared with pembrolizumab alone in patients with previously untreated metastatic nonsmall-cell lung cancer (NSCLC), but the difference did not reach statistical significance, according to the phase III EVOKE-03/KEYNOTE D46 study.



